Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
PR Newswire —
Technology Selectively Shuts Down Cancer Reproducing Cells Patent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast Cells NEW YORK, March 31, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused...